Feds open criminal probe into opioid makers

Pharmaceutical companies are under fire again for their role in the national opioid abuse epidemic and, this time, it could be criminal. Federal prosecutors have opened a criminal probe to determine if pharmaceutical companies intentionally allowed the flow of opioid drugs, The Wall Street Journal reported.

The investigation could be the largest prosecution of drug companies related to their actions and impact on the opioid epidemic if criminal charges are brought. Six companies, including Teva Pharmaceuticals, Mallinckrodt, Johnson & Johnson, Amneal Pharmaceuticals, AmerisourceBergen and McKesson, are facing grand jury subpoenas from the U.S. attorney’s office in the Eastern District of New York, according to the WSJ.

Drug companies are already facing thousands of lawsuits from individual states for their role in opioid harms, with Purdue Pharma filing for bankruptcy as part of a $10 billion settlement deal to resolve all pending litigation against the company, which is the maker of the powerful opioid OxyContin.

The companies facing the federal criminal investigation have denied wrongdoing, stating they’ve followed “all laws around the manufacture and distribution of opioid prescription painkillers,” the WSJ reported.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”